Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
67.31
+0.33 (0.49%)
At close: Apr 14, 2026, 4:00 PM EDT
67.44
+0.13 (0.19%)
After-hours: Apr 14, 2026, 4:58 PM EDT

Halozyme Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
7,9757,9275,8874,6857,6905,529
Market Cap Growth
0.42%34.64%25.65%-39.07%39.09%-4.70%
Enterprise Value
10,0099,9276,7975,8498,8205,575
Last Close Price
67.3167.3047.8136.9656.9040.21
PE Ratio
26.2926.2913.9417.6039.5114.68
Forward PE
8.368.8510.389.7721.9217.89
PEG Ratio
-0.550.550.900.910.46
PS Ratio
5.715.685.805.6511.6512.47
PB Ratio
161.61162.3916.1855.9145.2928.07
P/TBV Ratio
169.19170.8317.0159.1847.1229.97
P/FCF Ratio
12.3712.3012.5712.5532.6818.55
P/OCF Ratio
12.2412.1712.2912.0632.0318.46
EV/Sales Ratio
7.177.116.697.0513.3612.58
EV/EBITDA Ratio
11.1517.8210.7413.8527.8119.99
EV/EBIT Ratio
12.2621.1712.3317.3332.9720.21
EV/FCF Ratio
15.5315.4014.5115.6737.4918.71
Debt / Equity Ratio
43.8943.894.1417.898.794.00
Debt / EBITDA Ratio
3.853.852.383.554.753.14
Debt / FCF Ratio
3.323.323.224.026.402.94
Net Debt / Equity Ratio
40.9740.972.5013.886.730.69
Net Debt / EBITDA Ratio
3.593.591.442.753.610.49
Net Debt / FCF Ratio
3.103.101.943.124.860.46
Asset Turnover
0.610.610.530.460.450.53
Inventory Turnover
1.441.441.181.691.811.42
Quick Ratio
3.303.306.505.074.547.10
Current Ratio
4.664.667.806.645.657.91
Return on Equity (ROE)
153.59%153.59%198.42%222.07%110.23%231.44%
Return on Assets (ROA)
13.87%13.87%23.16%15.27%14.75%53.09%
Return on Invested Capital (ROIC)
18.02%18.02%33.64%20.63%25.58%169.66%
Return on Capital Employed (ROCE)
21.95%21.95%31.11%20.27%19.83%48.16%
Earnings Yield
3.97%3.80%7.17%5.68%2.53%6.81%
FCF Yield
8.08%8.13%7.96%7.97%3.06%5.39%
Buyback Yield / Dilution
4.26%4.27%3.56%4.56%4.22%-3.77%
Total Shareholder Return
4.26%4.27%3.56%4.56%4.22%-3.77%
Updated Feb 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q